Key terms

About DVAX

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DVAX news

Apr 01 4:27pm ET Dynavax Appoints Interim CFO During MacDonald’s Leave Mar 19 10:09am ET Dynavax (NASDAQ:DVAX) Offers Potentially Robust Growth at a Rich Valuation Mar 12 4:26pm ET Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy Feb 23 9:45am ET Dynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ Rating Feb 23 9:42am ET Dynavax price target raised to $29 from $28 at H.C. Wainwright Feb 23 8:50am ET Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX) and EDAP TMS (EDAP) Feb 23 12:15am ET Dynavax Technologies: A Stable Hold Amidst a Catalyst-Deficient Forecast Feb 22 11:15pm ET Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating Feb 22 4:04pm ET Dynavax sees 2024 Heplisav-B product revenue $265M-$280M Feb 22 4:03pm ET Dynavax reports Q4 EPS 0c, consensus (1c) Feb 01 9:58am ET Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls Feb 01 4:43am ET Dynavax initiated with a Neutral at Goldman Sachs Feb 01 2:16am ET Dynavax Hold Rating: Solid Performance Counterbalanced by Priced-In Prospects Jan 09 9:10am ET Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Dynavax (DVAX) Jan 09 6:32am ET Dynavax’s Strong Growth Prospects and Robust Vaccine Pipeline Merit a Buy Rating Jan 08 2:05pm ET Dynavax (DVAX) Receives a Buy from TD Cowen Jan 08 9:03am ET Dynavax sees FY23 HEPLISAV-B vaccine net product revenue about $213M Jan 08 9:02am ET Dynavax sees Q4 HEPLISAV-B vaccine net product revenue about $51M

No recent news articles are available for DVAX

No recent press releases are available for DVAX

DVAX Financials

1-year income & revenue

Key terms

DVAX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DVAX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms